Company Profile

Company Description

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. It specializes in monoclonal antibodies targeting the neonatal Fc receptor (FcRn) to reduce harmful autoantibodies in patients. The company's lead candidate aims to treat conditions like myasthenia gravis, thyroid eye disease, and chronic inflammatory demyelinating polyneuropathy. With a strong pipeline and research-driven approach, it seeks to address unmet medical needs in immunology. The firm collaborates with leading institutions to advance its therapies through clinical trials, aiming to improve outcomes for patients with debilitating autoimmune disorders.